Derived Psychoactive Cannabis Product Perceptions and Use Among a Sample of US Young Adults

Overview

Journal Addict Behav

Specialties Psychiatry
Social Sciences

Date 2024 Sep 27

PMID 39332229

Authors

Cassidy R LoParco

Matthew E Rossheim

Yuxian Cui

Darcey M McCready

Katelyn F Romm

Yan Wang

Y Tony Yang

Patricia A Cavazos-Rehg

Carla J Berg

Affiliations

Soon will be listed here.

Abstract

Aims: To characterize derived psychoactive cannabis product (DPCP) perceptions and use among US young adults.

Methods: We analyzed 2023 survey data among 4,031 young adults (ages 18-34), comprising ∼ 50 % reporting past-month cannabis use. Multivariable regressions examined sociodemographics, cannabis use, and DPCP risk perceptions in relation to: 1) past-month DPCP use (yes/no), 2) past-month number of DPCP use days, and 3) among those reporting no past-month DPCP use, future likelihood of DPCP use.

Results: In this sample (M = 26.3, 59.8 % female, 64.9 % White, 19.4 % Hispanic), DPCP awareness (67.5 %), lifetime use (41.7 %), and past-month use (24.4 %) differed by past-month cannabis use versus nonuse (87.0 % vs 48.8 %, 68.7 % vs 15.9 %, 45.6 % vs 4.2 %, respectively). Those aware learned about them mainly from friends/family (44.5 %) and believed DPCPs were required to be tested and approved to be safe (70.3 %) or were approved by the US Food and Drug Administration (59.0 %). Those who ever used DPCPs most often used delta-8 (69.7 %) and delta-9 (44.4 %) THC and for curiosity (55.5 %), belief of federal legality (34.1 %), and friends' suggestion (34.0 %). Correlates of past-month DPCP use, using more frequently, and higher likelihood of future use were: lower DPCP perceived harm and higher perceived addictiveness. Living where non-medical cannabis was illegal, higher perceived social acceptability, being Black (vs. White), and past-month cannabis use were also correlated with past-month use (but not frequency) and future likelihood of use.

Conclusions: Efforts are needed to better understand DPCPs' risks and correct consumer misperceptions. Relatedly, DPCP regulation, including marketing and distribution, is crucial.

References

Bergeria C, Strickland J, Spindle T, Kalaba M, Satyavolu P, Feldner M . A crowdsourcing survey study on the subjective effects of delta-8-tetrahydrocannabinol relative to delta-9-tetrahydrocannabinol and cannabidiol. Exp Clin Psychopharmacol. 2022; 31(2):312-317. DOI: 10.1037/pha0000565. View

LoParco C, Rossheim M, Walters S, Zhou Z, Olsson S, Sussman S . Delta-8 tetrahydrocannabinol: a scoping review and commentary. Addiction. 2023; 118(6):1011-1028. DOI: 10.1111/add.16142. View

Winstock A, Lynskey M, Maier L, Ferris J, Davies E . Perceptions of cannabis health information labels among people who use cannabis in the U.S. and Canada. Int J Drug Policy. 2020; 91:102789. DOI: 10.1016/j.drugpo.2020.102789. View

Rossheim M, LoParco C, Henry D, Trangenstein P, Walters S . Delta-8, Delta-10, HHC, THC-O, THCP, and THCV: What Should We Call These Products?. J Stud Alcohol Drugs. 2023; 84(3):357-360. DOI: 10.15288/jsad.23-00008. View

Rossheim M, LoParco C, Berg C, Tillett K, Trangenstein P, Henry D . Derived psychoactive cannabis products and 4/20 specials: An assessment of popular brands and retail price discounts in Fort Worth, Texas, 2023. Drug Alcohol Depend. 2024; 256:111119. DOI: 10.1016/j.drugalcdep.2024.111119. View

Rossheim M, LoParco C, Walker A, Livingston M, Trangenstein P, Olsson S . Delta-8 THC Retail Availability, Price, and Minimum Purchase Age. Cannabis Cannabinoid Res. 2022; 9(1):363-370. PMC: 11071109. DOI: 10.1089/can.2022.0079. View

Kruger D, Bone C, Meacham M, Klein C, Kruger J . THC-O-Acetate: Scarce Evidence for a Psychedelic Cannabinoid. J Psychoactive Drugs. 2023; 56(4):563-567. DOI: 10.1080/02791072.2023.2230573. View

Kruger D, Kruger J . Consumer Experiences with Delta-8-THC: Medical Use, Pharmaceutical Substitution, and Comparisons with Delta-9-THC. Cannabis Cannabinoid Res. 2021; 8(1):166-173. DOI: 10.1089/can.2021.0124. View

Akpunonu P, Baum R, Reckers A, Davidson B, Ellison R, Riley M . Sedation and Acute Encephalopathy in a Pediatric Patient Following Ingestion of Delta-8-Tetrahydrocannabinol Gummies. Am J Case Rep. 2021; 22:e933488. PMC: 8594112. DOI: 10.12659/AJCR.933488. View

10.

Bhalla I, Stefanovics E, Rosenheck R . Clinical Epidemiology of Single Versus Multiple Substance Use Disorders: Polysubstance Use Disorder. Med Care. 2017; 55 Suppl 9 Suppl 2:S24-S32. DOI: 10.1097/MLR.0000000000000731. View

11.

Livne O, Budney A, Borodovsky J, Walsh C, Shmulewitz D, Fink D . Delta-8 THC use in US adults: Sociodemographic characteristics and correlates. Addict Behav. 2022; 133:107374. PMC: 9245337. DOI: 10.1016/j.addbeh.2022.107374. View

12.

Rossheim M, Tillett K, Vasilev V, LoParco C, Berg C, Trangenstein P . Types and Brands of Derived Psychoactive Cannabis Products: An Online Retail Assessment, 2023. Cannabis Cannabinoid Res. 2024; 9(6):1478-1481. PMC: 11685292. DOI: 10.1089/can.2023.0266. View

13.

Babalonis S, Raup-Konsavage W, Akpunonu P, Balla A, Vrana K . Δ-THC: Legal Status, Widespread Availability, and Safety Concerns. Cannabis Cannabinoid Res. 2021; 6(5):362-365. PMC: 8664123. DOI: 10.1089/can.2021.0097. View

14.

Walker A, LoParco C, Rossheim M, Livingston M . #Delta8: a retailer-driven increase in Delta-8 THC discussions on Twitter from 2020 to 2021. Am J Drug Alcohol Abuse. 2023; 49(4):491-499. PMC: 11022156. DOI: 10.1080/00952990.2023.2222433. View

15.

Allara E, Ferri M, Bo A, Gasparrini A, Faggiano F . Are mass-media campaigns effective in preventing drug use? A Cochrane systematic review and meta-analysis. BMJ Open. 2015; 5(9):e007449. PMC: 4563251. DOI: 10.1136/bmjopen-2014-007449. View

16.

Kruger D, Amila K, Kaplan S, Redfield J, Stacy T, Agarwal V . A Content Analysis of Social Media Discussions on THC-O-Acetate. Cannabis. 2023; 6(2):13-21. PMC: 10361800. DOI: 10.26828/cannabis/2023/000164. View

17.

Kruger D, Korach N, Kruger J . Requirements for Cannabis Product Labeling by U.S. State. Cannabis Cannabinoid Res. 2021; 7(2):156-160. PMC: 9070747. DOI: 10.1089/can.2020.0079. View

18.

LoParco C, Kong A, Yockey R, Sekhon V, Olsson S, Rossheim M . Factors Associated with Delta-8 THC Retail Availability in Fort Worth, Texas, 2021-2022. Subst Use Misuse. 2024; 59(6):840-846. PMC: 11072389. DOI: 10.1080/10826084.2024.2305793. View

19.

LoParco C, Olsson S, Greene K, Livingston M, Henry D, Trangenstein P . How Are Retailers Describing Delta-8 THC?A Mixed-Methods Study in Fort Worth, Texas. J Stud Alcohol Drugs. 2023; 84(2):298-302. PMC: 10761301. DOI: 10.15288/jsad.22-00287. View

20.

Leas E, Nobles A, Shi Y, Hendrickson E . Public interest in ∆-Tetrahydrocannabinol (delta-8-THC) increased in US states that restricted ∆-Tetrahydrocannabinol (delta-9-THC) use. Int J Drug Policy. 2021; 101:103557. PMC: 9126323. DOI: 10.1016/j.drugpo.2021.103557. View